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Drugs of abuse have a long history in humanity. Currently however, a subject of great interest is 
the phenylalkylamine family of drugs. Not only is the abuse liability of interest but also the 
potential therapeutic expansion of the capabilities of this family of drugs by utilizing the unique 
stereospecific effects of the newly discovered hybrid compounds. Based upon prior data of N-
Alkyl 4-MA the enantiomers of N-Methyl, N-Ethyl, and N-Propyl were analyzed in hDAT, 
hNET, and hSERT. It was found that there was a negative correlation between chain length and 
potency and dopaminergic component. In agreement with the currently established paradigm it 
was also found that in almost all cases the S(+) enantiomer was the more potent.  
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I. Scientific Background  
1. Drugs of Abuse 
Humanity has a long and widespread history of psychoactive drug use.  Archaeological 
and historical evidence suggests that 13,000 years ago the betel nut, who’s active compound is 
arecoline, was chewed in Timor. Records also indicate use of the betel nut almost 11,000 years 
ago in Thailand, as well as the use of the coca plant, active ingredient cocaine, in the western 
regions of South America about 5,000-7,000 years ago (Sullivan & Hagen, 2002) . The list of 
evidence for psychoactive drug abuse goes on with similar stories found across the world. 
Psychoactive drug abuse truly became an issue however when artificial synthesis and isolation of 
the active compounds began, the most notable being the synthesis of amphetamine by Romanian 
chemist Lazar Edeleanu in 1887 (History of Amphetamines, 2017).  
 
Figure 1.1 Structure of Amphetamine (Alere, 2017) 
 
It was not until the early 1920’s however, that amphetamines were perceived as 
pharmaceutically useful. The explosion of amphetamine abuse began during the Second World 
War, militaries around the world even supplied their soldiers with amphetamine rations 
throughout the war. Amphetamines were then also prescribed by physicians for everything from 
weight-loss and fatigue to depression and ADHD. It was not until the 1960’s that widespread 
consumption of amphetamines began to show on a large scale the negative effects of 
amphetamine abuse. It was also in the 1960’s that research began to indicate that amphetamines 
were in fact quite addictive, instead of simply habituating like caffeine. The initial epidemic of 
  
2 
 
abuse was ascertained to be iatrogenic in nature, however a newer problem arose beginning in 
the 1980’s of a culture of illicit drug which resulted in a resurgence of the amphetamine abuse 
epidemic that is present today (Rasmussen, 2008).
 In tandem with the rise of abuse of amphetamines, was the abuse of other stimulants such 
as cocaine, and ecstasy (MDMA). With the crackdown by the FDA and the federal government, 
many began to synthesize synthetic amphetamines or designer drugs in order to avoid the current 
regulation by the government. In 2012, when bath salts became an issue discussed nationally, 
they were still available for legal purchase over the counter or online (Gershman & Fass, 2012). 
However as news stories began to pour in the federal government took action and scheduled and 
banned many of the known compounds circulated as “bath salts”.  
 Investigations into the underlying mechanisms behind drug abuse and abuse li-
ability have identified the dopaminergic pathways as the prominently affected areas in substance 
abuse. The dopaminergic pathways primarily consist of the mesolimbic system in the brain. The 
two regions of greatest interest in the mesolimbic/dopaminergic pathway are the Nucleus 
Accumbens (NA) and the Ventral Tegmental Area (VTA) (Alcaro et al., 2007). 
          
Figure 1.2 Illustration of Meso-lymbic pathway and Dopaminergic tracts and interactions with 
other tracts (Russo and Nestler, 2013) Figure 1.3  Illustration of addiction pathway 
(https://commons.wikimedia.org/wiki/File:%CE%94FosB.svg)
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The neurons in the VTA and NA undergo a depletion of dopamine and dopamine receptors upon 
chronic use of many drugs of abuse leading to increased substance seeking behavior to 
continually meet the increasing demand for the substance (Blum et al., 2015). It is yet to be 
discovered how dopamine specifically contributes to the addiction state, initially it was thought 
that dopamine’s hypothesized role in hedonic behavior was what lead to addiction. However, 
experiments have demonstrated that dopamine is not required for a hedonic response in animal 
studies (Berridge & Robinson 1998). Nonetheless it has been established that all drugs of abuse 
elicit a notable increase in synaptic dopamine in the nucleus accumbens. The primary source of 
this increase in synaptic dopamine has been identified as the ventral tegmental area where the 
somas of the dopamine releasing neurons are located (Johnson & North 1992, Jones et al. 1998, 
Tapper et al. 2004, Waldhoer et al. 2004, Justinova et al. 2005). 
 
2. Abuse Liability  
Abuse liability in drugs targeting the nervous system is typical measured by a ratio of 
dopaminergic to serotonergic activity. Those that, either by neurotransmitter release  stimulation 
or re-uptake inhibition, increase synaptic concentrations of dopamine are typically considered to 
be at high risk for abuse. Recent findings however found that certain drugs that have moderate to 
significant serotonergic activity can decrease abuse liability of certain compounds. 
   
Table 2.1 Transporter Mediated Release from Rat Brain Synaptosomes (Bonano et al., 2014) 
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One of the prominent examples is 3,4-Methylenedioxymethamphetamine otherwise 
known as MDMA or ecstasy.  MDMA has significant serotonergic and dopaminergic activity but 
shows relatively low abuse liability in animal studies. Meanwhile methamphetamine which is a 
highly addictive substance contains a significantly larger dopaminergic component. In addition a 
trend observed when modifying the para position of the phenyl group in methcathinone that the 
larger & more bulky the substituent group the more the molecule had decreased affinity for DAT 
and increased in SERT. This was demonstrated both by the ICSS and synaptosome experiments 
(Bonano et al., 2014).  
Abuse liability in human subjects is a significantly intricate concept and methods to 
establish clear criteria for liability have yet to yield a simple answer.  However currently as 
accepted by researchers and the United States Drug Enforcement Agency (DEA), the typical 
profile of a drug that has high abuse liability includes positive subjective effects, i.e. “euphoria” 
or a“high” sensation (Horton et al., 2013), but in experimental settings the DAT vs SERT 
selectivity of drugs is a good index to predict abuse liability (Bonano et al., 2014).  
3. Monoamine Transporters 
  In addition to the regulatory mechanisms of the dopaminergic systems, the potential of 
effects of adrenergic and serotonergic systems have been implicated in the modulation or 
attenuation of drugs of abuse and abuse liability. These neuronal tracts, contain specific types of 
neurons called monoamine neurons that produce, store , and release monoamine 
neurotransmitters. The monoamine neurotransmitters in this case are norepinephrine, dopamine, 
and serotonin (Rothman & Baumann, 2003). These neurons contain the corresponding 
monoamine transporters (MATs)  as well, in humans these would be hSERT, hDAT, and hNET.  
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 The monoamine transporters all belong to the solute carrier 6 (SLC6) gene family formed 
by structurally related proteins that use the Na+ driving force to concentrate substrates against 
their chemical gradient (Kristensen et al., 2011). These MATs are localized to the perisynaptic 
clefts of the neurons and are crucial for the monoamine re-uptake and termination of monoamine 
transmission (Torres, Gainetdinov, & Caron, 2003). The MAT’s contain 12 transmembrane 
domains with some conserved structures in between different transporters. There are 617 
residues in hDAT, 620 residues in hNET, and 630 residues in hSERT.  (Bruss, Hurt, Chen). 
  
Figure 3.1 Illustration of localization of MATs (Torres et al., 2003) 
 
The initially proposed mechanism of coupling was that the substrate would bind to the 
externally facing conformation of the transporter and that sodium and chloride mediated 
conformational changes in the transporter caused it to push into its inward facing conformation 
and transport the substrate along with a specific number of ions (Jadetzky, 1966). Experiments 
conducted on platelet serotonin (5HT) transport seemed to indicated that chloride ions 
specifically were required to transport serotonin in either direction.  Nelson and Rudnick further 
established that it was not an electrogenic demand for chloride but an allosteric one. They did so 
by substituting other more electronegative compounds, that did not improve transport, as well as 
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changing the membrane potential. Even after changing membrane potential chloride was need 
for serotonin transport. In the experiments chloride ions lowered the Km and raised the Vmax for 
5HT transport strongly supporting the assertion that chloride had a direct effect on the 
transporter. In addition, the transport of serotonin required the presence of intracellular 
potassium for efficient transport of 5HT (Nelson & Rudnick 1982; Nelson & Rudnick 1979). It 
was further discovered that serotonin transport required sodium to be bound and transported. The 
transport seemed to depend on the stoichiometric coupling of sodium and 5HT due to the simple 
kinetics and saturability of the transporter with relation to the sodium gradient. It was also 
concluded, based on the experimental data, that serotonin and sodium were transported in a 1:1 
ratio (Talvenheimo, Fishkes, Nelson & Rudnick, 1983) . Based upon the prior experiments if 1 
Na+ goes in and 1 K+ goes out in the transport of serotonin it should be an electroneutral 
mechanism with no current (Gu et al, 1994).  
Unexpectedly, however, an experiment conducted by Mager et al in 1994 in Xenopus 
oocytes expressing a cloned rat 5-HT transporter showed three separate currents. The first 
current that was identified was a transport associated current upon addition of 5HT to the 
solution, and was maintained while 5HT was in solution and expired after removal of 5HT. The 
second current they identified was a transient current that occurred in the absence of 5HT and 
triggered by strong hyperpolarization  and was blocked by the addition of 5HT. The third and 
final current was a small leak current observed in the absence of 5HT and it is blocked by uptake 
inhibitors. The most notable of the three currents, with regards to the function of the transporters, 
was the first current (the substrate-induced current). According to prior research 5HT transport 
was purported to be electroneutral and yet there was a clear transport associated current in the 
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oocytes. The experiment also postulated that the conducting states of SERT reflected the 
behavior of ionic channels rather than carriers (Mager et al, 1994). 
Further experiments demonstrated that the premise of the alternating access theory to be 
inaccurate or incorrect. In a cut-open oocyte voltage clamp experiment Adams and DeFelice 
discovered the transporter was simultaneously accessible to sodium and chloride ions binding 
internal and externally, while also asserting that the large transport associated current was 
indicative of the transporter behaving like an ion channel rather than a solute carrier. Varying 
internal and external ionic concentrations were used while simultaneously measuring current 
across the membrane to validate these assertions. It was also posited that K+ did not in fact 
compete with 5HT binding on the inward facing portion of the transporter based on competition 
binding assays (Adams & Defelice, 2003).  
Further experiments in hDAT also supported the hypothesis that the MATs mechanism 
was akin to that of an ion channel. Using two electrode voltage clamping experiments in 
Xenopus oocytes it was established that the transport current seen in hDAT were significantly 
greater than expected based on the assumed fixed stoichiometric ratio of 2 Na+:1Cl-:1 Dopamine 
(DA+) (Sonders et al., 1997).  The effect was also demonstrated in hNET in which the 
stoichiometric prediction did not match the measured current generated by the transport. 
However the assertions in the final experiments seek to reconcile the original and rising theories 
behind monoamine transport, suggesting that the MATs have multiple modes of transport (Galli, 
Blakely, DeFelice, 1996). 
The drugs that act on the transporters typically fall into two categories. The first category 
being those termed ‘inhibitors’ that bind the transporter to block neurotransmitter uptake. The 
second type termed ‘substrates’ bind to the transporter, are subsequently transported into cells, 
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and typically evoke release of neurotransmitters by reverse transport (Kahlig et al, 2005; 
Khoshbouei et al, 2003; Rothman and Baumann, 2006; Scholze et al, 2000). Many drugs that are 
substrates on the specific transporters share structural and biochemical similarities to the 
endogenous neurotransmitters associated with the transporter. It should be noted that while each 
transporter corresponds to a specific neurotransmitter, both hNET and hDAT transport dopamine 
and  norepinephrine. 
 Not only can substrates and blockers be differentiated by the binding mechanism and 
downstream effects, but also by electrophysiological signature. Substrates, by way of the 
transport mechanism & transporter, induce an inward sodium current inducing a localized 
depolarization of the membrane. Meanwhile blockers hinder the constitutive “leak” current 
producing an apparent outward hyperpolarizing current. (Cameron et al, 2013; Solis, 2017; Solis 
et al, 2012). It has been suggested that the magnitude of substrate-induced current of a substrate  
is correlated with long-term depletion of neurotransmitter in the brain (Baumann et al, 2014a; 
Fleckenstein et al, 2007).   
 
4. Voltage-gated Calcium Channels 
Monoamine transporters induced current by taking advantage of the sodium differential 
across the membrane and use the gradient of ions to transport neurotransmitters/substrates 
(Nelson & Rudnick, 1979). The depolarization by the monoamine transporters leads to affected 
activity of membrane ion channels. Membrane ion channels are membrane proteins that form 
pores in the lipid bilayer and help to sustain the resting membrane potential. In addition, voltage-
gated channels that modulate ion conduction as a function of the electrical potential across the 
membrane are important to generate action potentials in excitable cells (Hille, 2001).  
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What makes calcium channels such an important researched topic with relation to MATs is 
the role of calcium as a secondary messenger.  Calcium signaling controls cellular functions 
from vesicle release to muscular contraction, and is one of the most important secondary 
messengers in the body. Calcium entry that is coupled with transporter activation is also an 
excellent tool for measuring compound activity upon the monoamine transporters. Upon 
activation of voltage-gated calcium channels there is an increase in intracellular level of calcium 
that triggers presynaptic vesicular fusion and neurotransmitter release (Catterall, 2000).  
The intracellular concentration of Ca2+ is maintained at a concentration of about 100nM 
(Triggle, 2006), while extracellular concentrations are 10,000 times greater at about 1mM 
creating a massive gradient. Calcium becomes toxic above certain concentrations and due to its 
role as a secondary messenger intracellular concentrations must be tightly regulated (Simmons, 
1988). A portion of the pumps that participate in calcium homeostasis reside in the plasma 
membrane, and a portion reside on the endoplasmic reticulum, where calcium may also be stored 
and released from. The plasma membrane Ca2+ ATPase (PMCA) functions together with the 
Na+/Ca2+ exchanger (NCX) at the plasma membrane in order to maintain the Ca2+ 
homeostasis. The NCX is classified as low-affinity, high-capacity, this classification indicates 
that it can help clear large amounts of calcium at high concentrations normally to restore resting 
levels of Ca2+ after activation (Brini and Carafoli, 2001). PMCA on the other hand is a high-
affinity and low-capacity pump that keeps the resting level of calcium in quiescence. 
The L-Type calcium channels are distinguished by their relatively long activation and high-
voltage threshold. T-type channels on the other hand are distinguished by their low voltage 
threshold. Both types are found in neurons (Tsien et al., 1988). Using whole-cell voltage 
clamping of dorsal root ganglion neurons N-type channels were identified. The N-type channels 
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require both a strong negative potential for removal of inactivation as well as a strong 
depolarization for activation (Nowycky, 1985). 
 
Table 4.1 Calcium channel sub-types (Catterall, 2000) 
 
 
 
P-type calcium channels were first identified in Purkinje neurons in 1989 (Llinas, 
Sugimori & Cherksey, 1989). The defining characteristic of the P-type channel was that they 
could be blocked by at low concentrations peptide toxin ω-Aga-IVA while the T-type, L-type, & 
N-type currents were not affected (Mintz, Adams & Bean, 1992). The Q-type channels are 
distinguished by their lower sensitivity to blockage by peptide toxin ω-Aga-IVA . Finally the R-
Type, first recorded in cerebellar granule neurons, are distinguished by their resistance to the 
subtype-specific organic and peptide calcium channel blockers (Tsien & Randall, 1995). 
Upon purification and analysis of calcium channels it was discovered that, unlike cardiac 
and skeletal muscles Ca2+ channels, neuronal Ca2+ channels contain α1, α2ẟ, and 𝛽 subunits 
but no 𝛽 subunit. The α1 is the primary subunit forming the actual ionic pore and the voltage 
sensing domain. Whereas the other subunits act as modulators of the activity of the calcium 
channel (Ahlijanian, 1990). 
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Figure 4.1 Illustration of Calcium Channel Structure (Khosravani, 2006)      
In experimental studies it was determined that expression of the α1 subunit alone was 
sufficient to produce functional Calcium channels. Despite being functional, the expressivity of 
the channels with only the α1 subunit was low. In addition the channel kinetics and voltage 
dependence of the calcium current were abnormal (Perez-Reyes et al., 1989). It was later 
discovered by using muscle cells and including different subunits that the inclusion of the α2ẟ 
subunit in addition to the 𝛽 subunit greatly normalized the behavior of the calcium channels and 
presented data in line with “normal” gating function (Lacerta et al., 1991). And in 1996 it was 
established, by use of transgenic animals, that 𝛽 subunit was necessary for L-type channels to 
function (Gregg et al., 1996). 
Figure 4.2 Voltage clamp 
experiments on myocytes of control animals (a) and of 𝛽-null animals (b) (Gregg et al., 1996). 
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 After demonstrating that the 𝛽1-𝛽4 subunits were present in the cerebral cortex by 
immunoblotting, the effects of each subtype were analyzed. It was determined using oocytes 
with the α1C (CaV1.2) subunit that the 𝛽1,3, & 4 subunits were permissive to voltage dependent 
calcium channel facilitation, whereas the 𝛽2 subunit was not. (Pichler et al., 1997; Cens, 
Mangoni, Richard, Nargeot & Charnet, 1996) Using oocytes again it was ascertained that the 𝛽3 
subunit allowed for larger currents and had a faster inactivation time than both the 𝛽2a and 𝛽2b 
subunits (Hullin et al., 1992).  
 
 
5. Monoamine Transporters & Calcium Channel Coupling 
Using whole cell voltage clamping a significant difference was observed not only between 
the L-type (CaV 1.2 & 1.3) and N-type channels studied (CaV 2.2), but also among the L-types. 
The CaV1.3 channels opened at very negative potential requiring very little change in voltage to 
activate them, and reaching half-conductance at negative voltages. The CaV 1.2 channels opened 
at moderately negative potentials requiring a moderate to significant change in voltage to 
activate, and reaching half-conductance at a slightly negative voltage. While the CaV 2.2 opened 
at potentials closer to 0 mV requiring a very significant change in voltage to activate, and 
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reaching half-conductance at values above 0 mV. 
 
Figure 5.1 Voltage dependence of CaV1.2, CaV1.3 and CaV2.2- mediated Ca2+ 
currents: HEK293T cells were co-transfected with β3, α2δ, and EGFP expression plasmids 
plus alternatively CaV1.3, CaV1.2 or CaV2.2 plasmids. The Ca2+ current (ICa) recordings 
were carried out at room temperature under constant perfusion. Test pulses in 5 mV steps 
for CaV2.2 or 10 mV steps for CaV1.2 and CaV1.3 were applied from a holding potential of 
−80 mV. Representative responses are shown for CaV1.3 (light grey circle), CaV1.2 (dark 
grey triangle) and CaV2.2 (black square) and the magnitude of the test potentials are 
indicated in mV(Cameron et al. 2015). 
 
Through experimentation with HEK293 cell lines expressing the human SERT and DAT it 
was discovered the transport of both endogenous and exogenous substrates not only induced a 
current but also indirectly activated voltage-gated calcium channels. 
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Figure 5.2 S(+)AMPH is more potent than DA producing Ca2+ signals in L-type Ca2+ channel- 
expressing Flp-hDAT cells. Traces and dose response in CaV 1.3 & CaV 1.2 channels (Cameron 
et al., 2015). 
 
The experiments established that the transporter-associated current was capable of opening 
CaV 1.3 channels, which are commonly found in serotonergic neurons responsible for 
pacemaking. It was also discovered that transport could activate CaV1.2 calcium channels, 
abundant in cardiac cells but are also present in the central nervous system. The transport was 
not able to activate the neuronal-type CaV2.2 channels that were transiently transfected into 
HEK293 cells (Ruchala et al., 2014; Cameron et al., 2015).  
6. N-Alkyl 4-Methylamphetamine 
A drug first synthesized and studied in the 1950’s, 4-methlyamphetamine (4-MA) 
temporarily faded into obscurity until about 2009. 4-MA made its resurgence in the European 
drug market, being marketed/sold as “speed” (EMCDDA, 2012). Preclinical research established 
that 4-MA is a non-selective transporter substrate, releasing both dopamine & serotonin from 
neurons  in vitro and in vivo (Bauman et al., 2011; Wee et al., 2005). While there is only a 
modicum of investigation into the pharmacological effects of 4-MA there is even less 
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investigation into the 4-MA analogs. It was for this reason that Solis et al. decided to investigate 
the effects of lengthening the N-alkyl chain of 4-MA and its effects on the interactions at DAT, 
NET, and SERT. The amine group was the primary site of modification based upon prior 
amphetamine and cathinone studies that explored amine, phenyl, and alkyl group substitutions 
(Rothman et al, 2012; Saha et al, 2015; Simmler et al, 2014). 
Solist et al. conducted, ICSS, synaptosome, HEK cell calcium assay, and Xenopus oocyte 
two-electrode voltage clamp experiments to analyze in depth the effects of lengthening the amine 
substituents.  
 
Figure 6.1 Trace overlays and dose response curves of HEK cell Calcium Screening assays of 
N-Alkyl 4MA analogs (Solis et al, 2017)  
It was discovered that the N-alkyl chain length is negatively correlated with the drug  
potency on the transporters across all experimental condition tested. It was also discovered that 
as the chain length increased the drug shifted from a substrate to a blocker in some of the 
transporters. In hDAT N-Methyl 4-MA was a substrate while N-Ethyl, Propyl, and Butyl 4-MA 
were all blockers. In hNET the transition happened between N-Ethyl and N-Propyl, while in 
hSERT the transition did not happen at all (Solis et al., 2017). In addition studies done in 
synaptosomes and using the Ca2+ assays to study the pharmacology of these drugs, agreed that 
lengthening the N-alkyl chain of 4MA, gradually decreases the DA releasing properties but 
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keeping the 5HT releasing effect of these drugs. This observations were further corroborated in 
in vivo assays using ICSS studies in rats, showing a decrease in abuse liability as the N-alkyl 
chain is lengthened on the 4MA scaffold.  
 
II. Experimental Objectives 
The objective of this study is to determine the potency and efficacy of stereoisomers of  
N-alkyl- 4-Methyl Amphetamines to produce or to block electrical currents through monoamine 
transporters. The understanding of the pharmacological profile that these compounds have on 
hDAT, hSERT and hNET are important to predict: 1)  its abuse liability and 2) its potential 
therapeutical use.   
 
III. Materials & Methodology  
1. Experimental Procedure 
To analyze the drug effects in hSERT, hDAT,  and hNET previously established Human 
Embryonic Kidney (HEK) cell lines with the transporters expressed were utilized. The cells were 
stored in liquid nitrogen for long term storage. The HEK cells would be removed from the liquid 
nitrogen, plated in Dulbeco’s Modified Eagle Medium (DMEM) in addition to 1% penicillin & 
streptomycin and 10% Hyclone fetal bovine serum. The cells were stored in incubators at 
physiological temperature and pH.  
 Three days prior to planned Calcium screening assay, the cells would be transferred to 96-well 
plates that had the wells coated in Matrigel (Corning) so as to insure that cells would not be 
dislocated when exposed to the perfusion of solution. The typical confluency at initial plating 
was about 20-40%. 
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After the cells had attached to the matrigel they needed to be transfected with the 
necessary calcium channels and subunits. For the purpose of consistency all cell lines were 
transfected with CaV 1.2 alpha, beta 3 subunit,  alpha 2 delta subunit, and EGFP. The addition of 
EGFP to the transfection mix was to assist in locating transfected cells underneath the 
microscope for analysis.  
The transfection agent used was Fugene 6. The transfection mix was injected directly 
above the cells in the DMEM media and allowed to continue transfection for a minimum of 4 
hours and a maximum of 7 hours. After the transfection was complete the media was drained and 
replaced with DMEM containing 1ug/mL of doxycycline to induce expression of the 
transporters. Three days after transfection is completed and the media is changed the cells are 
removed from the incubator and the plate is cut so that only select numbers of wells remain 
exposed to the room temperature during the experiment. After cutting the plate the lanes to be 
used for experimentation immediately are drained of their current media and loaded with 50uL of 
imaging solution with 2 ug/mL of Fura-2AM. After a 25 minute loading time solution is drained 
again and the cells are washed for 20 minutes with imaging solution. 
 
Figure 8.1  Illustration of Calcium as a biosensor (Cameron, et al, 2015) Structure of 
Ratiometric imaging dye Fura-2 (Fura-2). 
The plates are then placed on an Olympus oil microscope with an attached imaging, 
recording, and perfusion system managed by the LiveAcquisition software. The camera takes 3 
pictures per second at two different wavelengths. The two protocols used are the substrate and 
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blocker protocols. For both protocols the perfusion system is placed slightly above the cells, with 
suction to prevent overflow, and the cells are washed with imaging solution (IS) for 10-20 
seconds. The beginning of each protocol is similar, they both start with a 10 second IS wash 
were images are acquired. 
          
Figure 8.2 Image of GFP fluorescence under the microscope. Montage of images & 
Fluorescence Ratio Trace captured from a representative experiment. R(-)-N-Methyl 4-MA in 
hSERT. 
Then both protocols have a 5s exposure to the control (5HT, DA, or NE), with images being 
captured. After the 5 second exposure to the control there is a 30 second wash with images being 
captured. In the substrate protocol after the 30 second wash there is a 5 second exposure to the 
compound being tested followed by another 30 second wash and the completion of the 
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experiment. In the blocker protocol the initial 30 second wash is followed by a 30 second 
exposure to the test drug, followed by a 5 second exposure to the control and the test drug at the 
same time, followed by a 30 second wash and completion of the experiment.                                    
2. Data Analysis  
After the experiments are done the images are analyzed by an offline analysis software. Regions 
of interest (ROIs) are selected manually after visual and objective analysis determined the cells 
to be within the accepted range. The primary measure for selecting cells/placing ROIs is to make 
sure the cells are not dislocated, do not burst, or are not affected by a calcium wave from other 
cells that is not due to the experiment. Typically about 5-7 cells are selected per well, each 
concentration from a dose response has approximately 3-5 wells for experimentation, and 
experiments are typically done on 2-3 separate days to evaluate consistency within the data 
gathered. Typical cells that had a clear response to the control and were not dislocated or 
affected by a calcium wave were assumed to be acceptable for analysis. 
 Data was then compiled and statistically analyzed to determine the EC/IC 50 values of 
each compound. To perform the analysis the selected ROIs for each well were compiled into 
separate files depending on the concentration being tested. Next the average of all the ROIs was 
used to select a maximum value range for the control and the test peaks. The maximum test 
values was divided by the maximum control values. For substrates the ratio corresponded to the 
excitation by the test drug, while for blockers it corresponded to the amount of signal from the 
control that was blocked. Trace overlays, created in Origin, had all values normalized to the 
maximum response of the control, so that all traces would be displayed as values between 0.0 
and 1.0.  
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 Dose response curves were generated using GraphPad’s Prism software by inputting the 
data and using the equation below:  
Y(x) = (Ymax) / 1 + 10exp[(logEC50 – logx) * n] 
In the equation, x is the concentration of experimental compound; Y(x) is the measured response; 
EC50 is the concentration of compound that gives rise to the half-maximal response; and n is the 
Hill slope parameter.  
3.Compounds under study 
 The compounds analyzed in the research presented in this paper are the enantiomers of 
N-methyl-1-(4-methylphenyl)propan-2-amine, N-ethyl-1-(4-methylphenyl)propan-2-amine, and 
N-propyl-1-(4-methylphenyl)propan-2-amine. The names are abbreviated below as S(+)/R(-)-N-
Methyl 4-MA, S(+)/R(-)-N-Ethyl 4-MA, and S(+)/R(-)-N-Propyl 4-MA.   
 
 
                      S(+)-N-Methyl 4-MA  R(-)-N-Methyl 4-MA   
 
           S(+)-N-Ethyl 4-MA  R(-)-N-Ethyl 4-MA 
  
21 
 
 
          S(+)-N-Propyl 4-MA  R(-)-N-Propyl 4-MA 
Figure 10.1 Structure of tested compounds  
 
 
 
 
 
 
IV. Results & Figures 
 
As we have shown before the co-expression of voltage-gated Ca2+ channels and MATs 
in HEK cells is a useful tool to study the interaction between a test drug and MATs (Cameron et 
al., 2015; Ruchala et al., 2014). As described above, substrates of MAT activate an inward 
current through the transporter that depolarizes the plasma membrane and this depolarization is 
strong enough to open L-type Ca channels (Cameron et al., 2015; Ruchala et al., 2014).  Since 
cells used in this study are loaded with the Ca2+ sensor (fura 2), the opening of the Ca2+ 
channels produce an instantaneous intracellular Ca2+ signal that is visualized as an increase in 
the ratio of fluorescence emission 340 nm/380 nm using fluorescence microscopy (fig 8.2).   
Using this experimental setting we are able to detect substrates of monoamine 
transporters, since they produce reliable Ca2+ signals, whereas blockers do not generate Ca2+ 
signals but can antagonize the action of a known substrate.  
The racemate N-Methyl 4MA showed an EC50 of 0.21 ± 0.02 uM, 0.25 ± 0.04 uM and 
0.48 ± 0.10 uM to produce Ca2+ signals when tested in cells expressing CaV1.2 and hDAT, 
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hNET or hSERT respectively (Solis, 2017).   The S(+) N-Methyl 4MA enantiomer tested in the 
same experimental setting showed an EC50 of  0.25 ± 0.035 uM, 0.19 ± .01 uM and 0.461 ± 0.04 
uM for hDAT, hNET and hSERT,  respectively. These results clearly show that the S(+) 
enantiomer of N-Methyl 4MA is responsible for most of the potency of the racemate compound. 
When the R(-)Methyl 4MA was tested in comparable experimental conditions, the EC50 
observed were 3.20 ± 1.19 uM,  0.19 ± 0.01 uM and 3.70 ±  0.40 uM for cells expressing hDAT, 
hNET and hSERT, respectively.  As seen for others amphetamine analogs, the R(-) enantiomer 
of N-Methyl 4MA show about one log unit less potency than the S(+) enantiomer for hDAT and 
hSERT cells. In contrast, S(+) and R(-) enantiomer of N-Methyl 4MA are equipotent in hNET 
expressing cells. In all cases studied the S(+) and R(-) enantiomers of N-Methyl 4MA were fully 
efficacious in generating Ca2+ signals suggesting that both enantiomers work as substrates in all 
three MATs. 
The racemate N-Ethyl 4MA showed 4.35 ± 0.61 uM (IC50), 0.73 ± 0.18 uM (EC50) and 
0.68 ± 0.09 uM (EC50) to block or produce Ca2+ signals when tested in cells expressing CaV1.2 
and hDAT, hNET or hSERT respectively (Solis, 2017).  The S(+) N-Ethyl 4MA enantiomer 
tested in the same experimental setting showed  2.73 ± 0.16 uM (IC50), 0.57 ± .08 uM (EC50) 
and 0.57 ± 0.01 uM (EC50) for hDAT, hNET (with CaV1.3) and hSERT,  respectively. The data 
obtained using the CaV1.2 sub-type does not exhibit enough of a dynamic range to be an 
accurate predictor of the EC50 in hNET with N-ethyl enantiomers. For the sake of the results 
description the data gathered by Harris will be used for comparison (Harris, 2016). When the R(-
)Ethyl 4MA was tested in comparable experimental conditions, the IC/EC50 observed were 
44.49 ± 17.04 uM (IC50),  1.17 ± 0.21 uM (EC50) and 1.62 ±  0.14 uM (EC50) for cells 
expressing hDAT, hNET and hSERT, respectively.  As seen for others amphetamine analogs, the 
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R(-) enantiomer of N-Ethyl 4MA show around one log unit less potency than the S(+) 
enantiomer for hDAT, hNET (when using data gathered with CaV1.3 channels), and hSERT 
cells (Harris, 2016). In hDAT the S(+) and R(-) enantiomers of N-Ethyl 4MA were fully 
efficacious in blocking Ca2+ signals suggesting that both enantiomers work as blockers in 
hDAT. In hSERT the enantiomers generated an equivalent calcium signal were fully efficacious 
substrates. However in hNET the enantiomers did not generate Ca2+ signals equivalent to the 
control and only reached 80% efficacy for the S(+) and 65% efficacy for the R(-) as substrates.  
These results suggest that the S(+) enantiomer of N-Ethyl 4MA is responsible for most of the 
potency of the racemate compound. 
The racemate N-Propyl 4MA showed 18.26  ± 3.60 uM (IC50), 14.35  ± 3.56 uM (IC50) 
and 0.68 ± 0.09 uM (EC50) to block or produce Ca2+ signals when tested in cells expressing 
CaV1.2 and hDAT, hNET or hSERT respectively (Solis, 2017).   The S(+) N-Propyl 4MA 
enantiomer tested in the same experimental setting showed 6.60 ± 2.30 uM (IC50), 6.66 ± 1.50 
uM (IC50) and 0.872  ± 0.12 uM (EC50) for hDAT, hNET and hSERT,  respectively.  When the 
R(-) N-Propyl 4MA was tested in comparable experimental conditions, the IC/EC50 observed 
were 37.92 ± 2.79 uM (IC50),  26.00 ± 3.51 uM (IC50) and 1.62 ±  0.14 uM (EC50) for cells 
expressing hDAT, hNET and hSERT, respectively. In hDAT the S(+) and R(-) enantiomers of 
N-Propyl 4MA were fully efficacious in blocking Ca2+ signals suggesting that both enantiomers 
work as blockers in hDAT. In hSERT the S(+) generated a fully efficacious Ca2+ signal acting 
as a substrate. The R(-) blocked calcium signal in hSERT at low concentrations but did generate 
some Ca2+ signal at very high concentrations giving the impression that it is a weak/partial 
substrate. In hNET the enantiomers both blocked Ca2+ signal, the S(+) was almost fully 
efficacious, and since R(-) only blocked ~50% of the signal at 30uM, further concentrations were 
  
24 
 
not tested. These results suggest that the S(+) enantiomer of N-Propyl 4MA is responsible for 
most of the potency of the racemate compound. 
 
 
 
 
 
 
Drug hDAT (uM +/- 
SEM) 
hNET (uM +/- SEM) hSERT (uM +/- 
SEM) 
N-Methyl 4MA 0.21 ± 0.02 0.25 ± 0.04 0.48 ± 0.10 
(S+)-N-Methyl 4MA 0.25 ± 0.035* 0.19 ± .01 0.461 ± 0.04* 
(R-)-N-Methyl 4MA 3.20 ± 1.19 0.19 ± .01 3.70 ±  0.40 
N-Ethyl 4MA 4.35 ± 0.61 0.73 ± 0.18 0.68 ± 0.09 
(S+)-N-Ethyl 4MA 2.73 ± 0.16* 0.23 ± ~0 [CaV1.2] 
0.57 ± .08 [CaV 1.3]* 
0.57 ± 0.01 * 
(R-)-N-Ethyl 4MA 44.49 ± 17.04 N/A** [CaV 1.2] 
1.17 ± 0.21 [CaV1.3] 
1.62 ±  0.14 
N-Propyl 4MA 18.26  ± 3.60 14.35  ± 3.56 2.44  ± 0.39 
(S+)-N-Propyl 4MA 6.60 ± 2.30* 6.66 ± 1.50* 0.872  ± 0.12 
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(R-)-N-Propyl 4MA 37.92 ± 2.79 26.00 ± 3.51 4.39  ± 1.38 
Table 11.1. Calculated EC/IC50. Darkened cells indicate compounds that were blockers, while 
cells with no fill indicate substrates.* indicates that the S(+) enantiomer IC/EC50 values are 
significantly different at p<0.01 compared to the R(-) enantiomer based upon an unpaired t-test. 
** Signal too small to estimate a reliable potency. CaV1.3 data from  (Harris, A.C.). All data 
gathered using CaV1.2 unless stated otherwise.  
 
 
 
 
 
 
 
 
 
 
 
Drug hDAT (nM +/- 
SEM) 
hNET (nM +/- SEM) hSERT (nM +/- 
SEM) 
(S+)-N-Methyl 4MA  109.2%±4.5   101.7%± 1.9 94% ± 2.9  
(R-)-N-Methyl 4MA  98%±13.7   90.1%± 1.8 107% ± 7.6  
(S+)-N-Ethyl 4MA  95.3%± 2.5 57.2%± 3.1 [CaV1.2] 
87.5% ±2.1 [CaV 1.3] 
91.3% ± 3.6 
(R-)-N-Ethyl 4MA 100% ± 18.9 ~35% [CaV 1.2] 
67.5%± 2.9 [CaV1.3] 
96% ± 3.3 
(S+)-N-Propyl 4MA 100%± 3.0 ~90%  83% ± 2.8 
(R-)-N-Propyl 4MA 76% ± 3.5 >50% 59.8%± 7.2 
Table 11.2 Calculated Efficacy, Darkened cells indicate compounds that were blockers, cells 
with no fill indicate substrates. 
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The IC/EC50 curves below and the traces overlays are visual representations of the data 
discussed and in the table above. 
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Figure 11.1  hDAT EC/IC50 Dose Response Curves 
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Figure 11.2 hNET EC/IC50 Dose Response Curves 
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Figure 11.3 hSERT EC/IC50 Dose Response Curves 
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                                   S(+)       R(-) 
 
N-Methyl-4-MA 
 
N-Ethyl-4-MA 
 
N-Propyl-4-MA 
Figure 11.4 hDAT Trace Overlays 
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                                   S(+)       R(-) 
 
N-Methyl-4-MA 
 
N-Ethyl-4-MA 
 
N-Propyl-4-MA 
Figure 11.5 hNET Trace Overlays 
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                                   S(+)       R(-) 
 
N-Methyl-4-MA 
 
N-Ethyl-4-MA 
 
N-Propyl-4-MA 
Figure 11.6 hSERT Trace Overlays 
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V. Discussion 
 Drug stereospecificity has long been a subject of interest in the pharmacological 
community. Stereospecificity of a compound is conferred by having at least one chiral center or a 
plane of symmetry. A chiral center is a carbon atom that has four different substituent groups. A 
plane of symmetry is essentially a point in space that if the molecule was divided by a line at that 
point each side of the molecule would be mirror image of the other side. Research over the years 
has consistently indicated a trend, at least in amphetamines, of the (+) enantiomer being more 
potent than the (-) enantiomer (Arnold, 2000) . Adderall, a commonly prescribed medication for 
attention deficit disorder, is a combination of D(+) and L(-) amphetamine salts in a 3:1 ratio 
favoring the D(+) enantiomer. The specific formulation of Adderall takes advantage of the 
specific effect of each enantiomer. The D/dextro-amphetamine typically acts as more of a CNS 
stimulant, while the L/levo-amphetamine acts more peripherally as well as eliciting a better 
response from some children (Smith & Davis, 1977; Westfall & Westfall, 2010; Lewin, Miller, 
Gilmour, 2011; Anthony, 2013; Arnold, 2000). This blend of the stereoisomers,  is just one 
example of how pharmaceutical formulation can optimize drug action when stereospecific 
effects is taken into account. 
As described in the result section the S(+) and R(-) enantiomers of the N-Alkyl 4-MA 
drugs seems to be consistent with the trends observed in D/(+)-Amphetamine and L/(-)-
amphetamine by Holmes and Rutledge in 1976. Their data showed that (+)-Amphetamine was 
notably more potent in SERT and DAT and mildly more potent in NET. Methamphetamine also 
demonstrates stereospecific activity akin to that of amphetamine. The (+) stereoisomer being 
similarly potent to the (-) stereoisomer in hNET, and more potent in hSERT and hDAT. The 
results presented here for N-Methyl-4MA enantiomers (that structurally are very similar to 
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Methamphetamine) almost directly mirrors this pattern and seems to  strengthen the evidence 
behind the current stereoselective paradigm in amphetamines and amphetamine like compounds 
(Holmes & Rutledge, 1976) (Rothman & Baumann, 2003). Interestingly, when the N-Alkyl 
chain is lengthened to obtain N-Ethyl 4MA and N-Propyl 4MA the equipotency of enantiomers 
on hNET gradually disappears, suggesting that small substituents in the N-alkyl position is 
important to preserve the lack of stereoselectivity of amphetamines on hNET.    
When we studied  N-Ethyl 4-MA enantiomers in hNET cells transfected with CaV1.2 the 
results showed that both enantiomers work as substrates, and are not fully efficacious to generate 
Ca2+ signals. The data obtained for R(-) N-Ethyl 4MA was not robust enough to get a reliable 
dose response curve (fig 12.1).  The decreased efficacy of N-Ethyl 4MA compounds compared 
to NE, can be explained by a restricted ability of these compounds to generate substrate-
associated currents on hNET; this could produce a reduced depolarization that would activate 
less Ca2+ channels, resulting in smaller Ca2+ signals.  The efficacy of N-Ethyl 4MA 
enantiomers to generate Ca2+ signals were significantly increased when CaV1.3 (Harris et al, 
2016) was used instead of CaV1.2 in comparable experimental settings (fig 12.1). CaV1.3 shows 
a 20 mV left shift in the voltage sensitive compared to CaV1.2 (Ruchala et al., 2014; Cameron et 
al., 2015), in other words, CaV1.3 can sense smaller levels of depolarization than CaV1.2.  Thus, 
the enhanced Ca2+ signals  measured when CaV1.3 was used, suggest that N-Ethyl 4MA 
enantiomers produce smaller currents associated to hNET activation compared to N-Methyl 
4MA and NE. It would be of great interest to study the effect of R(-) N-Ethyl 4-MA on release 
studies in synaptosomes, the prediction would be that these compound would produce partial 
release. 
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Figure 12.1 N-Ethyl in hNET transfected with CaV 1.3 channels (Harris, A.C.). N-Ethyl in 
hNET transfected with CaV 1.2 channels. 
 
 
Until recently the current paradigm with regards to calcium channels and minimum 
subunits required for ‘normal’ function states that there must be an α1 subunit along with  𝛽 and 
α2ẟ subunits (Gregg et al, 1996). However there was a similarity of data gathered in hDAT when 
comparing it to data gathered under the exact same conditions by Harris et al, while not using the 
α2ẟ or 𝛽3 subunits. The experiments with CaV 1.2α1 subunit, the  𝛽3 subunit, and the α2ẟ 
subunit, provided nearly the exact same results as Harris et al. This runs counter to the minimum 
requirements for functional calcium channels as suggested by Gregg et al. By comparing both 
data sets it was demonstrated that, for a reason yet to be discovered, the 𝛽 and α2ẟ subunits are 
not necessary for ‘normal function’ of at least the CaV 1.2α1 subtype. To further explore the 
mechanism behind this discrepancy studies evaluating differing calcium channel subtypes in 
different cell cultures should be conducted without overexpression of the calcium channels as 
done by Gregg et al. This overexpression may have led to altered activity of the calcium 
channels, leading the experimenters to incorrectly assert the necessity of the 𝛽 and α2ẟ subunits.  
Minor technical differences aside, this novel calcium screening assay that co-expresses 
calcium channels and monoamine transporters, has allowed for the rapid & predictive profiling 
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of novel compounds. The assay has allowed for differentiation of substrates, blockers, and now 
hybrid compound pharmacology. With this profiling it is also possible to estimate therapeutic 
and abuse liability implications of the novel compounds. For example the S(+)-N-Methyl 
enantiomer exhibited a pharmacological profile notably similar to MDMA, it had significant 
potency in all three MATs but maintained a low dopaminergic (DAT): serotonergic (SERT) 
ratio. Meanwhile the R(-)-N-Methyl enantiomer displayed remarkably selective substrate at 
hNET, almost 20 times more potent at hNET than hDAT or hSERT. Among many amphetamine 
compounds it is unique to identify those that are primarily selective releasers in NET and with 
the observations here R(-)-N-Methyl 4-MA could potentially be a good candidate for clinical 
drug trials that require that degree of selectivity. The similarity of the profile of S(+)-N-Methyl 
4-MA to MDMA also highlights it as a potential non-scheduled substance to be used in place of 
MDMA in clinical trials for PTSD therapy (Sessa, 2017). Meanwhile the profile of R(-)-N-
Methyl 4-MA makes it a potential good candidate for an attention deficit disorder (ADD) and 
attention deficit/hyperactivity disorder (ADHD) medication with lower abuse liability, and more 
adrenergic selectivity due it to its slight stimulant effects and strong adrenergic component.   
The stereospecificity alone does not dictate the activity of the drug, it is also important to 
understand which class of drug each compound falls under. As discussed previously each drug 
typically falls within two classes.  The first class being those termed ‘inhibitors’ that bind the 
transporter to block neurotransmitter uptake. The second type termed ‘substrates’ bind to the 
transporter, are subsequently transported into cells, and typically evoke release of 
neurotransmitters by reverse transport of compounds that acted on the MATs (Kahlig et al, 2005; 
Khoshbouei et al, 2003; Rothman and Baumann, 2006; Scholze et al, 2000) . Recent experiments  
have evidenced that there is a third class of compounds. This third class of compound displays 
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hybrid activity, acting as “full” or “partial” substrate in one or more MATs while acting as 
blocker in the others (Blough et al., 2014). This new classification of drug adds another layer of 
complexity and flexibility to the therapeutic capacity of amphetamine like compounds and 
potentially other monoamine transporter agonists and antagonists.  
It is not until the N-Ethyl compounds that we begin to observe the hybrid activity of these 
compounds. The N-Ethyl enantiomers are of great interest not only due to its hybrid activity, 
seen in both enantiomers, but also due their selectivity for hSERT and their extremely weak 
effect at hDAT. While it may seem that they are selective for hNET and hSERT, by examining 
the efficacy at each transporter it should be noted the N-Ethyl 4-MA enantiomers are at least 
20% less efficacious in hNET (Table 11.2). The S(+)-N-Propyl enantiomer also exhibits similar 
activity with a remarkable favoritism towards SERT as a substrate, taking into account that it 
work as a weak blocker in hDAT and hNET. These drug profiles appear to be unique and not 
directly comparable to any known compound outside those analyzed in the experiments done on 
the N-Alkyl 4-MA analogs.  
While no current drug profile fits exactly, the selective serotonergic releasing and weak 
dopaminergic blocking activity seen by both of the N-ethyl enantiomers and the S(+)-N-propyl 
enantiomer is similar to the profile of a drug named Fenfluramine. Fenfluramine blocks the 
reuptake of 5HT while simultaneously increasing transport mediated release. It was initially 
prescribed as an anorectic to help manage exogenous obesity. However it was withdrawn from 
the public market in 1997 in the United States of America, after reports of heart valve disease, 
pulmonary hypertension, and cardiac fibrosis due to its interaction with a serotonergic 
transporter subtype found in the heart (NCBIPC, 2017; Connolly et al., 1997; Abenheim et al., 
1996). The molecular mechanism behind why fenfluramine was causing such widespread issue 
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was not discovered until a few years later. It was discovered the impaired function of the 5-
HT2B receptor subtype lead to cardiomyopathy, hypertrophy, and disruption of the intercalated 
disks in recombinant mice when compared to wild type mice (Nebigil et al., 2001). Ten years 
later it was discovered that the 5-HT2B receptor subtype was required for the anorectic effects of 
Fenfluramine by using wild-type and knockout mice studies (Banas et al., 2011). Due to the 
similarity of the compounds (Figure 12.2) The S(+)-N-Ethyl or S(+)-N-Propyl enantiomer may 
be utilized as possibly safer anorectic, if further experiments demonstrate lower non-specific 
effect of these drugs on the 5HT2B receptor.   
  
Figure 12.2 Structural similarities of S(+)-N-Ethyl 4-MA,   S(+)-Fenfluramine,  
S(+)-N-Propyl 4-MA 
 
 It is also possible that all three S(+)-N-Alkyl 4-MA analogs could potentially be used as 
part of a replacement therapy protocol for amphetamines, amphetamine like compounds, or other 
monoamine effector drugs. The shift of drugs from substrate (agonist) to blocker (antagonist) 
allows for a much more well rounded approach to replacement therapy based on agonist and 
antagonist advantages in stimulant disorders as summarized by Grabowski et al (Grabowski, 
Shearer, Merrill & Negus, 2004).  
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Agonist Antagonist 
Decrease drug use+ Decrease drug use+ 
Diminish use related risks+ Diminish use related risks+ 
Patient acceptance good+ Patient acceptance poor− 
Potentially enhanced compliance+ Noncompliance common− 
Familiarity with effects/side effects+ Potential significant side effects− 
Table 12.1 Summary of advantages (+) and disadvantages (−) of agonist and antagonist 
approaches in stimulant disorders (Grabowski, Shearer, Merrill & Negus, 2004) 
Based upon the trend of the drugs established by the calcium screening assay (Table 
11.1) and the relationship between the DAT:SERT ratio and abuse liability established by 
Bonano et al., a protocol proceeding towards a less addictive replacement drug could be 
established (Bonano et al, 2014). The protocol could initially introduce the S(+)-Methyl analog 
and progress towards the S(+)-Propyl analog by first reducing the amount of drug and then 
switching to the longer chain analog until dependency is abolished.  
More data is required to make definitive assertions about the compounds tested. An ideal 
next step would be to analyze compound activity in vivo through microdialysis studies. However 
there are already many strong therapeutic and experimental possibilities opened up by 
preliminary analysis of these compounds.
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VI. Conclusion 
● S(+) enantiomers were consistently more potent than the R(-) enantiomers, with the 
exception of the N-Methyl analogs in hNET. This clearly further established importance 
of the drug stereospecificity in amphetamine like compounds. 
● There was a negative correlation between chain length and potency implying that the N-
alkyl chains were necessary to interact with binding pocket or at least allosterically 
regulate binding. 
● There was a negative correlation between chain length and dopaminergic activity 
implying that increased N-alkyl chain length could be used to attenuate dopaminergic 
component of other amphetamine like compounds. 
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